Further Confirmation of Candidate Neoantigen
in Chat
MHC I on the surface of tumor cells is capable of presenting highly specific peptides called neoantigens. Since they are not expressed in normal cells, these peptides are ideal targets for tumor immunotherapy and tumor vaccines. In recent years, immunotherapy based on tumor neoantigens has received significant attention, but the accurate identification of tumor-specific neoantigens from the cell membrane surface remains a difficult challenge. Traditional methods for tumor neoantigen identification use genomic or transcriptomic sequencing techniques to identify tumor-specific mutations (mostly point mutations) from DNA or mRNA, and then generate candidate peptides that have the potential to become tumor-specific neoantigens by software prediction only. Learn more: confirmation of neoantigen